Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s11239-019-01907-9 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Differential Cardiotoxicity of Ibrutinib Versus Chemoimmunotherapy in Chronic Lymphocytic Leukemia: A Population-Based Study.
J Clin Med
December 2024
Clatterbridge Cancer Centre NHS Foundation Trust, Liverpool L7 8YA, UK.
Chronic lymphocytic leukaemia (CLL) is the most common form of leukaemia among adults, particularly in Western nations. The introduction of Bruton's tyrosine kinase (BTK) inhibitors as a treatment of CLL, namely, ibrutinib, which is a first-generation BTK inhibitor, has significantly improved the treatment landscape for CLL. However, ibrutinib has been associated with an increased risk of atrial fibrillation (AF) and hypertension.
View Article and Find Full Text PDFReal-World Evidence on Adverse Events and Healthcare Resource Utilization in Patients with Chronic Lymphocytic Leukaemia in Spain Using Natural Language Processing: The SRealCLL Study.
Cancers (Basel)
November 2024
Haematology Department, Hospital Universitario de la Princesa, 28004 Madrid, Spain.
The SRealCLL study described the occurrence of adverse events (AEs) and healthcare resource utilization in patients with chronic lymphocytic leukaemia (CLL) using artificial intelligence in a real-world scenario in Spain. We collected real-world data on patients with CLL from seven Spanish hospitals between January 2016 and December 2018, focusing on their AE and healthcare service utilization. Data extraction from electronic health records of 385,904 patients was performed using the EHRead technology, which is based on natural language processing and machine learning.
View Article and Find Full Text PDFInteractions of warfarin with COVID-19 vaccine/drugs, monoclonal antibodies, and targeted anticancer agents from real-world data mining.
Front Pharmacol
November 2024
Department of Infectious Diseases and Public Health, City University of Hong Kong, Hong Kong SAR, China.
Objective: This study aims to examine the unresolved drug-drug interactions of warfarin using real-world data.
Methods: Electronic medical records from a hospital in Shanghai, China, were used to summarize drug-related problems (DRPs) among inpatients taking warfarin in 2022. Additionally, adverse event data for warfarin from January 2004 to December 2023 were extracted from the U.
Real-world effectiveness and safety of ibrutinib in patients with chronic lymphocytic leukemia in Japan: the Orbit study.
Int J Hematol
November 2024
Department of Medical Technology, Faculty of Medical Technology, Niigata University of Pharmacy and Medical and Life Sciences, Niigata, Japan.
Article Synopsis
- * The Orbit study aimed to evaluate real-world outcomes for adults with CLL/SLL in Japan treated with ibrutinib between July 2018 and December 2020, including 246 patients in total.
- * After 36 months, the study showed an 80.9% progression-free survival rate for first-line treatment and 67.2% for relapsed cases, with common significant side effects including bleeding and infections, underscoring ibr
Expert Opinion on Managing Adverse Reactions Associated With Acalabrutinib Therapy: A Delphi Consensus From France.
Clin Lymphoma Myeloma Leuk
October 2024
Department of Pharmacy, Paris Public Hospital at Home (HAD AP-HP), University Hospitals of Paris, Paris, France.
Article Synopsis
- - Acalabrutinib, a more advanced treatment for chronic lymphocytic leukemia, has a better safety profile than older drugs but lacks clear guidelines on managing its side effects, prompting a study to establish best practices.
- - A team of medical professionals across France found that hospital pharmacists should evaluate drug interactions before starting patients on acalabrutinib and advised against using it with certain medications that can increase risks of toxicity or reduce effectiveness.
- - The study highlighted the need for monitoring blood pressure during treatment, outlined protocols for managing procedures, and suggested headache management strategies, demonstrating the importance of teamwork in improving patient care while using acalabrutinib.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!